# US 2019/0153474 A1 · Cns gene delivery using peripheral administration of aav vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153474 A1
- Document ID: US20190153474A1
- Status: Published application
- Kind: A1
- Application number: 16/214,214
- Filed: 2018-12-10
- Published: 2019-05-23
- Earliest claimed: 2007-07-23
- Assignees: Genethon; Centre National De La Recherche Scientifique
- Applicants: Genethon; Centre National De La Recherche Scientifique
- Inventors: Martine Barkats
- Web page: https://patentgrep.com/patent/US20190153474A1

## CPC

- C12N 15/86: Viral vectors
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases.

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A method for expressing a transgene in cerebrospinal fluid secretory cells of a subject, said method comprising peripherally administering to said subject an effective amount of a single-stranded adeno-associated virus (AAV) vector comprising an AAV9 capsid and a single-stranded genome comprising said transgene.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the AAV vector is a pseudotyped AAV vector.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the AAV vector comprises a genome comprising AAV2 inverted terminal repeats, said genome being encapsidated in an AAV9 capsid.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the AAV vector has a replication defective AAV genome lacking functional Rep and Cap encoding viral sequences.

### Claim 18 (depends on 14)

The method according to claim 14, wherein expression of the transgene is controlled by a ubiquitous promoter.

### Claim 19 (depends on 14)

The method according to claim 14, wherein expression of the transgene is controlled by a regulated promoter.

### Claim 20 (depends on 14)

The method according to claim 14, wherein expression of the transgene is controlled by a tissue-specific promoter.

### Claim 21 (depends on 14)

The method according to claim 14, wherein the AAV vector is administered by intravascular injection.

### Claim 22 (depends on 14)

The method according to claim 14, wherein the AAV vector is administered by intravenous injection.

### Claim 23 (depends on 14)

The method according to claim 14, wherein the AAV vector is administered by intra-arterial injection.

### Claim 24 (depends on 14)

The method according to claim 14, wherein the transgene encodes a therapeutic protein

### Claim 25 (depends on 14)

The method according to claim 14, wherein the transgene encodes a therapeutic protein selected from growth factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, and any protein known to be mutated in pathological disorders such as the “survival of motor neuron” protein (SMN).

### Claim 26 (depends on 14)

The method according to claim 14, wherein said subject suffers from a central nervous system (CNS) disorder selected from neurodegenerative diseases, neuromuscular diseases, lysosomal diseases, trauma, bone marrow injuries, cancers of the nervous system, demyelinating diseases, autoimmune diseases of the nervous system, neurotoxic syndromes, sleeping disorders.
